Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716580 | 0.84 | ACE2 (0.42) | TSHRMAPTCHRM1AKR1A1CHRM3 | |
| SCHEMBL7758037 | 0.82 | ACE2 (0.55) | TSHRMAPTACE2 | |
| SCHEMBL18920279 | 0.82 | ACE2 (0.55) | TSHRMAPTACE2 | |
| SCHEMBL467228 | 0.78 | TSHR (0.44) | TSHRMAPT | |
| SCHEMBL9818162 | 0.77 | — | — | |
| SCHEMBL3768394 | 0.76 | LMNA (0.56) | MAPTACE2 | |
| SCHEMBL301262 | 0.75 | MAPT (0.55) | TSHRMAPTCHRM1AKR1A1CHRM3 | |
| SCHEMBL15216700 | 0.75 | TSHR (0.46) | TSHRMAPTCHRM1AKR1A1CHRM3 | |
| SCHEMBL1198338 | 0.75 | MAPT (0.55) | TSHRMAPTCHRM1AKR1A1CHRM3 | |
| SCHEMBL3120866 | 0.75 | MAPT (0.55) | TSHRMAPTCHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354342-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR. | SHAHID MUSLIM D (US) | 2016-12-08 | — | — | US | claimed |
| US-9457011-B2 | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor | SHAHID MUSLIM D (US) | 2016-10-04 | — | — | US | claimed |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | SHAHID MUSLIM D (US) | 2015-08-27 | — | — | US | claimed |
| US-11273145-B2 | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor | SHAHID MUSLIM D (US) | 2022-03-15 | — | — | US | disclosed |
| US-20160354342-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR. | SHAHID MUSLIM D (US) | 2016-12-08 | — | — | US | disclosed |
| US-9457011-B2 | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor | SHAHID MUSLIM D (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | SHAHID MUSLIM D (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273145-B2 | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor | ALAD, FABP6, ALOX15B | TSHR 1529/4885MAPT 3090/4885CHRM1 4373/4885 |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | FABP6, ALAD, SLC10A2 | TSHR 1544/4885MAPT 3475/4885CHRM1 4274/4885 |
| US-20160354342-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR. | ALAD, ALOX15B, FABP6 | TSHR 1716/4885MAPT 3035/4885CHRM1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.